Carlsmed Stands Out Among Surgical Equipment Rivals

Got story updates? Submit your updates here. ›

Carlsmed (NASDAQ:CARL) is a medical technology company pioneering AI-enabled personalized spine surgery solutions, including its aprevo Technology Platform. The company is focused on becoming the standard of care for spine fusion surgery, offering customized surgical plans and implants powered by AI algorithms. Carlsmed's approach aims to address limitations of traditional spine fusion surgery and improve patient outcomes.

Why it matters

Carlsmed's personalized spine surgery solutions could disrupt the $13.4 billion U.S. spine fusion market by reducing revision surgeries and improving long-term patient outcomes. The company's technology represents an innovative alternative to traditional one-size-fits-all spine fusion procedures.

The details

Carlsmed's aprevo Technology Platform includes AI-enabled software, customized interbody implants, and single-use surgical instruments. The platform is designed to optimize spinal alignment and reduce the need for revision surgeries compared to traditional spine fusion. Carlsmed has 510(k) clearance from the FDA for its lumbar interbody fusion solutions and is developing the platform for cervical spine fusion as well.

• Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries in November 2024.
• Carlsmed plans to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026.

What’s next

Carlsmed plans to continue building out its aprevo Technology Platform for cervical fusion procedures by pursuing additional FDA clearances for advancements to its cervical software platform and personalized plating solutions.